Sero-prevalance of anti-R7V antibody in HIV infected
patients in the Federal Capital Territory (FCT), Nigeria
Yusuf, K. M.1, Shugaba, A.2, Az
zubair, M. K.1 and Agwale, S.3
Biotechnology Development Agency, No. 16 Dunukofia Street,
Former C.A.C. Building, Area 11, Abuja Nigeria.
of Biochemistry, University of Maiduguri, PMB 1069,
Biotech Limited Abdu Abubakar Street, Opposite New keffi
Hotel, Keffi, Nasarraawa State.
*Corresponding author. E-mail:
+234-08055122330. Fax: 09-3145472.
Accepted 3 November, 2009
Studies in some parts of the world have shown that Anti-R7V
antibodies, which neutralize 100% of the different variant’s
panel (targeted against a beta2-microglobulin epitope
acquired when the virus is released by budding) in vitro,
are found in 30 to 50% of naïve HIV positive patients, but
even more in so-called “long-term survivor’’ patients with a
close to 90% correlation.
The seroprevalence of Anti-R7V antibody was therefore
investigated in HIV patients attending clinic within the
Federal Capital Territory (FCT) and compared with HIV
negative patients. Correlation between the presence of the
antibody and the clinical status of patients was also
investigated. The HIV positive patients were categorized
into drug naïve and drug experienced subjects and their
Anti-R7V antibody together with CD4 counts were determined
using Anti-R7V ELISA kits and BD FACS count, respectively.
About 47.2% of the HIV-infected patients tested positive for
the Anti-R7V antibody while 25.2% were negative for this
antibody. Patients with Anti-R7V antibody had a mean CD4
count (355 ± 19.2) significantly (P < 0.05) higher than that
of Anti-R7V antibody negative patients (215 ± 42.6). Also it
was observed that Anti-R7V antibody was significantly (P <
0.05) lower in drug experienced patients as compared to drug
naïve patients. The significance of these findings is
discussed. It was concluded that
antibody may be a natural immunity against HIV-infection in
drug naïve HIV patients and that the synthesis and release
of this antibody may decrease with ARD treatment.
HIV, AIDS, anti-R7V antibodies, Nigeria, CD4 count.